Search results
Results from the WOW.Com Content Network
The IM formulations of these three atypical antipsychotics are considered to be at least as effective or even more effective than the IM administration of haloperidol alone or haloperidol with lorazepam [15] [16] [17] (which is the standard treatment of agitation in most hospitals) and the atypicals have a dramatically improved tolerability due ...
The FDA approved the CardiAssist ECP system for the treatment of angina, acute myocardial infarction and cardiogenic shock under a 510(k) submission in 1980 [1] [failed verification] Since then, additional ECP devices have been cleared by the FDA for use in treating stable or unstable angina pectoris, acute myocardial infarction, cardiogenic shock, and congestive heart failure.
Chronic care models such as the delivery of chronic disease management programs may be effective for patients with long-term chronic conditions. For patients with asthma, having a coordinated program involving multiple health care professionals can make improvements in aspects such as patients perceived quality of life, lung functioning and the ...
To enter the drug treatment system, such as it is, requires a leap of faith. The system operates largely unmoved by the findings of medical science. Peer-reviewed data and evidence-based practices do not govern how rehabilitation facilities work. There are very few reassuring medical degrees adorning their walls.
The most common use of SCS is failed back surgery syndrome (FBSS) in the United States and peripheral ischemic pain in Europe. [4] [5]As of 2014 the FDA had approved SCS as a treatment for FBSS, chronic pain, complex regional pain syndrome, intractable angina, as well as visceral abdominal and perineal pain [1] and pain in the extremities from nerve damage.
Ranolazine was approved by the FDA in January 2006, for the treatment of patients with chronic angina as a second-line treatment in addition to other drugs. [13] In 2007 the label was updated to make ranolazine a first-line treatment, alone or with other drugs. [13] In April 2008 ranolazine was approved by the European EMEA for use in angina. [25]
The incidence of chronic disease has increased as mortality rates have decreased. [1] It is estimated that by 2030 half of the population of the USA will have one or more chronic conditions. [2] According to the CDC, 6 out of 10 adults in the U.S. are managing at least one chronic disease and 42% of adults have two or more chronic conditions. [3]
Chronic meningitis is a long-lasting inflammation of the membranes lining the brain and spinal cord (known as the meninges). By definition, the duration of signs, symptoms and inflammation in chronic meningitis last longer than 4 weeks. [ 2 ]